Beam Therapeutics Inc.

We are a biotechnology company focused on developing precision genetic medicines. Our platform integrates gene editing and delivery technologies with internal manufacturing. Our core technology is proprietary base editing, which aims to precisely target a single base in the genome without creating a double-stranded break in the DNA. This method uses a chemical reaction to achieve precise, predictable, and efficient genetic outcomes at the targeted sequence. Our proprietary base editors consist of two main components: a CRISPR protein bound to a guide RNA, modified to avoid double-stranded breaks, and a base editing enzyme, such as a deaminase, which performs the chemical modification of the target DNA base. We believe this design offers a more precise and efficient edit compared to traditional gene editing methods. We are also developing various delivery modalities, including both ex vivo and in vivo approaches, tailored to specific tissue types. This combination of base editing and tissue-specific delivery forms a targeted, efficient, precise, and versatile gene editing system capable of gene correction, gene silencing, gene activation, gene modification, and/or simultaneous multiplex editing of several genes. Our objective is to advance a broad portfolio of base editing programs against distinct, genetically validated editing targets and to expand the reach of our programs through an innovative platform business model.